Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-28

FDA Approved: ZEPZELCA — Supplemental Application (Jazz Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZEPZELCA (lurbinectedin) submitted by Jazz Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zepzelca (lurbinectedin)

Snippet

SUPPL AP for ZEPZELCA (LURBINECTEDIN)